Researching the effectiveness and the relevancy of combined therapy with Polygynax and Pharmatex in the cases with proved HPV infection or suspicion of such infection
The HPV infection is the most frequent sexually transmitted disease. It can be estimated that approximately 80% of young women would be infected with it till their fiftieth anniversary. When there is a HPV infection in the zone of the external sexual organs and the introitus, in 90% of the cases, the cervix is also engaged. In the majority of the cases, there is a parallel fungal infection with often presence of bacterial component which sets the low local immunity and creates ideal environment for HPV infection. This fact serves as basis for the application of the therapeutic combination of Polygynax+Pharmatex at this first stage. Relying on the virucide action of the local non-hormonal contraception - Pharmatex and the wide action range of Polygynax, the present clinical research confirmed the rightfulness of our thesis and the efficiency of the suggested therapeutic model.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2011 |
---|---|
Erschienen: |
2011 |
Enthalten in: |
Zur Gesamtaufnahme - volume:50 Suppl 2 |
---|---|
Enthalten in: |
Akusherstvo i ginekologiia - 50 Suppl 2(2011) vom: 10., Seite 44-8 |
Sprache: |
Bulgarisch |
---|
Beteiligte Personen: |
Hristamyan, A [VerfasserIn] |
---|
Anmerkungen: |
Date Completed 31.05.2012 Date Revised 01.12.2018 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM217202888 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM217202888 | ||
003 | DE-627 | ||
005 | 20231224033528.0 | ||
007 | tu | ||
008 | 231224s2011 xx ||||| 00| ||bul c | ||
028 | 5 | 2 | |a pubmed24n0724.xml |
035 | |a (DE-627)NLM217202888 | ||
035 | |a (NLM)22524141 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a bul | ||
100 | 1 | |a Hristamyan, A |e verfasserin |4 aut | |
245 | 1 | 0 | |a Researching the effectiveness and the relevancy of combined therapy with Polygynax and Pharmatex in the cases with proved HPV infection or suspicion of such infection |
264 | 1 | |c 2011 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 31.05.2012 | ||
500 | |a Date Revised 01.12.2018 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a The HPV infection is the most frequent sexually transmitted disease. It can be estimated that approximately 80% of young women would be infected with it till their fiftieth anniversary. When there is a HPV infection in the zone of the external sexual organs and the introitus, in 90% of the cases, the cervix is also engaged. In the majority of the cases, there is a parallel fungal infection with often presence of bacterial component which sets the low local immunity and creates ideal environment for HPV infection. This fact serves as basis for the application of the therapeutic combination of Polygynax+Pharmatex at this first stage. Relying on the virucide action of the local non-hormonal contraception - Pharmatex and the wide action range of Polygynax, the present clinical research confirmed the rightfulness of our thesis and the efficiency of the suggested therapeutic model | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Arsenicals |2 NLM | |
650 | 7 | |a Contraceptive Agents |2 NLM | |
650 | 7 | |a Drug Combinations |2 NLM | |
650 | 7 | |a Polymyxins |2 NLM | |
650 | 7 | |a Nystatin |2 NLM | |
650 | 7 | |a 1400-61-9 |2 NLM | |
650 | 7 | |a acetarsol, dimethicone, neomycin, nystatin, polymyxin drug combination |2 NLM | |
650 | 7 | |a 78891-94-8 |2 NLM | |
650 | 7 | |a Neomycin |2 NLM | |
650 | 7 | |a I16QD7X297 |2 NLM | |
773 | 0 | 8 | |i Enthalten in |t Akusherstvo i ginekologiia |d 1962 |g 50 Suppl 2(2011) vom: 10., Seite 44-8 |w (DE-627)NLM000046221 |x 0324-0959 |7 nnns |
773 | 1 | 8 | |g volume:50 Suppl 2 |g year:2011 |g day:10 |g pages:44-8 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 50 Suppl 2 |j 2011 |b 10 |h 44-8 |